Tracy Murray Stewart1, Apurva A Desai2, Michael L Fitzgerald3, Laurence J Marton4, Robert A Casero5. 1. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB 1, Room 562, Baltimore, MD, 21287, USA. tmurray2@jhmi.edu. 2. Illinois Cancer Specialists, Elgin, IL, 60123, USA. 3. , Apex, NC, 27502, USA. 4. Cancer Commons, Los Altos, CA, 94022, USA. 5. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB 1, Room 551, Baltimore, MD, 21287, USA. rcasero@jhmi.edu.
Abstract
PURPOSE: Polyamines are essential for the sustained proliferation and biomass required by tumor cells. Bis-alkylated polyamine analogs are nonfunctional competitors of natural polyamines. Of these, PG-11047, a second-generation unsaturated analog of the polyamine spermine, has demonstrated anticancer activity in cell lines and animal models of multiple cancer types. This report describes the first phase I clinical trial to investigate PG-11047 in patients with advanced refractory metastatic solid tumors. METHODS: Forty-six patients were treated with 60-min intravenous infusions of PG-11047 using a 28-day dosing cycle with treatments on days 1, 8, and 15. Doses ranged from 50 to 750 mg. The treatment period consisted of at least two cycles. RESULTS: The maximum tolerated dose of PG-11047 administered at this dosing schedule was 610 mg. Dose-limiting toxicities (DLT) were mainly gastrointestinal, including oral/anal mucositis and diarrhea; other DLTs included one case each of angioedema and a grade 3 alanine aminotransferase (ALT) increase. The most common adverse effects were fatigue and anorexia. Stable disease was documented in 30% of patients. CONCLUSION: Results of this phase I trial suggest that PG-11047 can be safely administered to patients on the once weekly dosing schedule described. The manageable toxicity profile and high MTD determination provide a safety profile for further clinical studies, including those in combination with current chemotherapeutic agents.
PURPOSE:Polyamines are essential for the sustained proliferation and biomass required by tumor cells. Bis-alkylated polyamine analogs are nonfunctional competitors of natural polyamines. Of these, PG-11047, a second-generation unsaturated analog of the polyamine spermine, has demonstrated anticancer activity in cell lines and animal models of multiple cancer types. This report describes the first phase I clinical trial to investigate PG-11047 in patients with advanced refractory metastatic solid tumors. METHODS: Forty-six patients were treated with 60-min intravenous infusions of PG-11047 using a 28-day dosing cycle with treatments on days 1, 8, and 15. Doses ranged from 50 to 750 mg. The treatment period consisted of at least two cycles. RESULTS: The maximum tolerated dose of PG-11047 administered at this dosing schedule was 610 mg. Dose-limiting toxicities (DLT) were mainly gastrointestinal, including oral/anal mucositis and diarrhea; other DLTs included one case each of angioedema and a grade 3 alanine aminotransferase (ALT) increase. The most common adverse effects were fatigue and anorexia. Stable disease was documented in 30% of patients. CONCLUSION: Results of this phase I trial suggest that PG-11047 can be safely administered to patients on the once weekly dosing schedule described. The manageable toxicity profile and high MTD determination provide a safety profile for further clinical studies, including those in combination with current chemotherapeutic agents.
Authors: Allison Pledgie; Yi Huang; Amy Hacker; Zhe Zhang; Patrick M Woster; Nancy E Davidson; Robert A Casero Journal: J Biol Chem Date: 2005-10-05 Impact factor: 5.157
Authors: Hillary A Hahm; David S Ettinger; Kathy Bowling; Beth Hoker; Tian Ling Chen; Yelena Zabelina; Robert A Casero Journal: Clin Cancer Res Date: 2002-03 Impact factor: 12.531
Authors: Frank L Meyskens; Christine E McLaren; Daniel Pelot; Sharon Fujikawa-Brooks; Philip M Carpenter; Ernest Hawk; Gary Kelloff; Michael J Lawson; Jayashri Kidao; John McCracken; C Gregory Albers; Dennis J Ahnen; D Kim Turgeon; Steven Goldschmid; Peter Lance; Curt H Hagedorn; Daniel L Gillen; Eugene W Gerner Journal: Cancer Prev Res (Phila) Date: 2008-06
Authors: Natalia A Ignatenko; Hagit F Yerushalmi; Ritu Pandey; Karen L Kachel; David E Stringer; Laurence J Marton; Eugene W Gerner Journal: Cancer Genomics Proteomics Date: 2009 May-Jun Impact factor: 4.069
Authors: Tracy Murray-Stewart; Elena Ferrari; Ying Xie; Fei Yu; Laurence J Marton; David Oupicky; Robert A Casero Journal: PLoS One Date: 2017-04-19 Impact factor: 3.240
Authors: Wen-Lin Kuo; Debopriya Das; Safiyyah Ziyad; Sanchita Bhattacharya; William J Gibb; Laura M Heiser; Anguraj Sadanandam; Gerald V Fontenay; Zhi Hu; Nicholas J Wang; Nora Bayani; Heidi S Feiler; Richard M Neve; Andrew J Wyrobek; Paul T Spellman; Laurence J Marton; Joe W Gray Journal: BMC Med Date: 2009-12-14 Impact factor: 8.775
Authors: Cassandra E Holbert; Jackson R Foley; Ao Yu; Tracy Murray Stewart; Otto Phanstiel; David Oupicky; Robert A Casero Journal: Med Sci (Basel) Date: 2022-08-22
Authors: Tracy Murray Stewart; Daniel Von Hoff; Michael Fitzgerald; Laurence J Marton; Carlos H Roberto Becerra; Thomas E Boyd; Paul R Conkling; Lawrence E Garbo; Robert M Jotte; Donald A Richards; David A Smith; Joe J Stephenson; Nicholas J Vogelzang; Hillary H Wu; Robert A Casero Journal: Cancer Chemother Pharmacol Date: 2020-11-19 Impact factor: 3.333